Crossmark

Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey

Crossref DOI link: https://doi.org/10.1016/j.artere.2022.01.002

Published Print: 2022-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Guijarro, Carlos

Civeira, Fernando

López-Miranda, José

Masana, Luis

Pedro-Botet, Juan

Pintó, Xavier

Valdivielso, Pedro

Mostaza, José María
License Information

Text and Data Mining valid from 2022-01-01
More Information

This article is maintained by: Elsevier

Article Title: Situation in 2020 of the requirements for the use of PCSK9 inhibitors in Spain: Results of a national survey

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2022.01.002

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.arteri.2021.07.002

Content Type: article

Copyright: © 2021 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.